Document:

Exhibit 10.13

 

DATED THE
15th DAY OF December 2017

 

BETWEEN

 

LIM HUI SING

 

LEONG YEE MING

 

(the “Vendors”)

 

AND

 

VITAXEL SDN. BHD.

(the “Purchaser”)

 

AND

 

VITAXEL USA

 

 

 

SHARE SALE AGREEMENT

IN RESPECT OF GRANDE LEGACY (BVI) INC

 

 

 

    	 	 	 

     

    

 

THIS AGREEMENT is made on the 15th
day of December 2017

 

BETWEEN

 

LIM HUI SING (NRIC No: A31045777),
whose residential address is at No 27, Jln Du 4/7, Taman Damai Utama, 47180 Puchong, Selangor.

 

AND

 

LEONG YEE MING (NRIC No: A41282606)
whose residential address is at 11-2-3, Menara Antara, Jln Bkt Ceylon Menara Antara, 50200 Kuala Lumpur, WP Kuala Lumpur.

 

(collectively, the “Vendors”,
and individually, a “Vendor”) of the first part;

 

AND

 

VITAXEL SDN. BHD. (Company No: 1013530U),
a company duly incorporated under the laws of Malaysia and having its business office at Wisma Ho Wah Genting, No 35, Jalan Maharajalela,
50150 Kuala Lumpur

 

(the “Purchaser”) of the
second part;

 

AND

 

VITAXEL GROUP LIMITED (Registration
No: E0556682013-0) is a company incorporated under the laws of Nevada, in the United States of America and having its registered
address at 1645 Village Center Circle, Ste. 170, Las Vegas, NV 89134

 

(“Vitaxel”) of the third
part.

 

RECITALS:

 

		A.	Grande Legacy Inc (BVI) (Company No.; 1769057), is a private company limited by shares incorporated
in British Virgin Islands and having its registered address at Vistra Corporate Services Centre, Wickhams, Cay II, Road Town, Tortola,
VG1110, British Virgin Islands (the “Company”). It is principally engaged in the business of E-commerce direct
selling (the “Business”) and has at the date of this Agreement, an issued and paid up share capital of United
States Dollars Four (USD4) consisting of four (4) issued ordinary shares of United States Dollars One (USD1) each (collectively,
the “Shares” and each, a “Share”).

 

		B.	The Vendors currently and collectively hold, free from any third-party interests or claims, four
(4) Shares, being 100% of the total issued and paid up share capital of the Company.

 

		C.	The Purchaser is desirous of purchasing and the Vendors are desirous of selling the number of Shares
set out against their respective names in Schedule 1 (the “Sale Shares”) at the Consideration as defined hereunder.

 

    	 	 	 

     

    

 

		D.	Vitaxel is a company listed in the OTC Market in the United States of America. Vitaxel wholly-owns
the Purchaser and will provide the Consideration in respect of the purchase of the Sale Shares by the Purchaser.

 

		E.	All parties hereto are agreeable to perform the sale and purchase of the Sale Shares between the
Vendors and the Purchaser (the “Transaction”) on the terms and subject to the conditions contained in this Agreement.

 

IT IS AGREED as follows:

 

		1	DEFINITIONS AND INTERPRETATION

 

		1.1	Definitions

 

	“Business Day”	means a day (other than a public holiday, Saturday and Sunday) on which commercial banks in Kuala Lumpur, Malaysia are open for the transaction of normal banking business;
	 	 
	“Confidential Information”	means all information not in the public domain and which is used in or which otherwise relates to the Company's business, its financial or other affairs, including, without limitation, information relating to:
	 	 
	 	(a) the marketing of products or services including, without limitation, financial information, targets, statistics, market share statistics, prices, market research reports and surveys, and advertising or other promotional materials;
	 	 
	 	(b) future projects, business development or planning, commercial relationships and negotiations; or
	 	 
	 	(c) all know-how which is owned by the Company and/or used or required to be used by the Company in or in connection with its business existing in any form (including, but not limited to that comprised in or derived from data, specifications, formulae, experience, drawings, manuals, component lists, instructions, designs and circuit diagrams, brochures, catalogues and other descriptions), 
	 	 
	 	existing in whatever form;
	 	 
	“Completion Date”	within six (6) months of this Agreement or any other date as agree by all parties.

 

    	 	 	 

     

    

 

	“Intellectual Property”	means all intellectual property rights including, without limitation, trademarks, service marks, trade names, domain names, logos, patents, inventions, database rights, copyrights, registered designs, design rights or applications for any of the foregoing and all other similar rights in any part of the world, in each case whether registered or unregistered including, without limitation, where such rights are obtained or enhanced by registration, any registration of such rights and applications, pending applications and rights to apply for such registrations and all renewals and extensions thereof existing in any part of the world, whether now known or in the future created;
	 	 
	“Intellectual Property Rights” 	means all Intellectual Property used, or required to be used, by the Company in, or in connection with its business and/or legally or beneficially owned by the Company;
	 	 
	“Sale Shares”	means four (4) Shares, representing 100% of the Shares to be purchased by the Purchaser from the Vendors in the proportions set out in Schedule 1; 
	 	 
	“Security Interest”	means any form of legal or equitable security interest or other encumbrance, including but not limited to any mortgage, assignment of receivables, debenture, lien, charge, pledge, title retention, right to acquire, hypothecation, option, pre-emptive or other similar right, right of first refusal, restriction, third-party right or interest, right of set off or counterclaim, equities trust or arrangement or any other type of preferential arrangement (including title transfers and retention arrangements or otherwise) or any other encumbrance whatsoever having similar effect, or an agreement, arrangement or obligation to create any of the foregoing;
	 	 
	“Stake Documents”	means the:
	 	 
	 	(a) share certificates for the Sale Shares; and
	 	 
	 	(b) undated duly executed transfer forms for the Sale Shares; 
	 	 
	 	and such other documents as may be necessary to ensure transfer of the Sale Shares to the Purchaser;
	 	 
	“Stakeholder”	means Chong Hui Leng (NRIC No: A40982479), whose residential address is at No. 7, Jalan Cheras Mewah 2, Taman Cheras Mewah, 56000 Kuala Lumpur;

 

    	 	 	 

     

    

 

		1.2	Interpretation

 

In this Agreement, unless the context requires otherwise:

 

		1.2.1	Any reference to:

 

		(a)	a person includes the legal personal representatives, successors and permitted assigns of that
person;

 

		(b)	a statute includes rules, regulations and any other subordinate legislation under it and consolidations,
amendments, re-enactments or replacements of any of them;

 

		(c)	“RM” or “Ringgit Malaysia” is a reference to Malaysian currency and “USD”
or United States Dollars” is a reference to the United States’ currency.

 

		(d)	the singular includes the plural and vice versa;

 

		(e)	a gender includes all genders;

 

		(f)	a date or time of day is a reference to Malaysian date or time.

 

		1.2.2	Headings and sub-headings are inserted for ease of reference only and do not affect the interpretation
of this Agreement.

 

		1.2.3	Anything or obligation to be done under this Agreement which requires or falls to be done on a
stipulated day, shall be done on the next succeeding Business Day, if the day upon which that thing or obligation is required or
falls to be done falls on a day which is not a Business Day.

 

		2	SALE AND PURCHASE OF SALE SHARES

 

		2.1	Sale and Purchase of Sale Shares

 

Each of the Vendors
shall, as legal and beneficial owners, sell the number of Sale Shares set out against their respective names in Schedule 1 and
the Purchaser, in full reliance upon the Vendors’ Warranties, shall purchase the Sale Shares, on a willing buyer willing
seller basis, free from any Security Interest and with all rights, benefits and entitlements attaching to the Sale Shares and accruing
as at and from the Completion Date (including the right to receive all dividends or distributions declared, made or paid on or
after the Completion) on the terms and subject to the conditions contained in this Agreement.

 

		2.2	Basis of Sale and Purchase

 

The Parties expressly
declare, acknowledge and agree that the sale and purchase of the Sale Shares pursuant to this Agreement is on the basis that as
at the Completion Date:

 

    	 	 	 

     

    

 

		2.2.1	the Company remains as a going concern;

 

		2.2.2	the Sale Shares are free from any Security Interest;

 

		2.2.3	the Vendors’, Purchaser’s and Vitaxel’s warranties are true and accurate.

 

		3	CONSIDERATION

 

		3.1	The aggregate consideration for the purchase of the Sale Shares shall be an aggregate sum of United
States Dollar Thirty Million Only (USD30,000,000) -the "Consideration", paid or payable by the Purchaser to the
Vendors by the issuance of Seventy-Five Million (75,000,000) shares or at USD0.40 per share, (“Vitaxel Shares”)
to the Vendors on the Completion Date. The Vitaxel Shares to be issued shall rank pari passu in all respects with the existing
issued shares of Vitaxel.

 

		3.2	The proportions of the Consideration, which is paid or payable to each Vendor, shall be in the
proportions set out against the respective names of the Vendors in Schedule 1.

 

		3.3	Receipt by each of the Vendors or their authorised representatives of the Vitaxel Shares shall
be an absolute discharge to the Purchaser of its obligation to pay the Consideration.

 

		3.4	In the event this Agreement is terminated or determined prior to Completion for any reason whatsoever,
the Vendors shall return the Vitaxel Shares immediately to the Purchaser.

 

		4	DEPOSIT OF STAKE DOCUMENTS

 

Upon the execution
of this Agreement, the Vendors will deposit the Stake Documents with the Stakeholder.

 

		5	DUTIES OF STAKEHOLDER

 

		5.1	Upon receipt, the Stakeholder will hold the Stake Documents
and release them in the following manner:

 

		5.1.1	deliver the Stake Documents in accordance with Clause 7 on the Completion Date; or

 

		5.1.2	deliver the Stake Documents to the Vendors in the event of termination of this Agreement.

 

    	 	 	 

     

    

 

		6	PENDING COMPLETION

 

		6.1	During the period commencing on the date of this Agreement
up to and including the Completion Date:

 

		6.1.1	the Vendors shall consult the Purchaser in advance on all material decisions taken in relation
to the Company;

 

		6.1.2	the Vendors shall procure that the Company shall preserve and maintain in full force and effect
its corporate existence;

 

		6.1.3	the Vendors shall procure that the Company shall carry on its Business as a going concern in the
ordinary and usual course and in a manner consistent with its past practices and use its reasonable endeavours to:

 

		(a)	preserve
and protect the Business as presently operated by it and the assets held by it; and

 

		(b)	retain its customers and employees.

 

		(c)	Make no changes in management personnel
or their compensation without prior consultation with the Purchaser

 

		(d)	Maintain the assets of the Company in
a state of repair and condition that complies with all legal requirements and is consistent with the requirements and normal conduct
of Company’s business;

 

		(e)	Comply with all legal requirements and
contractual obligations applicable to the operations of the Business;

 

		(f)	Continue in full force and effect the
insurance coverage under the policies attached;

 

		(g)	Maintain all books and records of the
Company in the ordinary course of business consistent with past practice;

 

		(h)	Not sell, transfer or otherwise dispose
of any of the Sale Shares or any interest in the Sale Shares;

 

		(i)	Not accept any dividend or other distribution
in respect of any of the Sale Shares;

 

		(j)	Not incur, make, assume or suffer to exist
any Security Interest or other matter affecting title to any of the Sale Shares;

 

		(k)	Not enter into any shareholder agreements,
voting trusts, restrictions on transfer or other agreements or instruments that would be binding on the Purchaser as the owner
of the Sale Shares;

 

    	 	 	 

     

    

 

		(l)	Take no action, and use their best efforts
to prevent the occurrence of any event or the existence of any condition that would result in any of the representations and warranties
of the Vendors in this Agreement not being true and correct.

 

		1.2	If any of the Vendors breaches a provision of this Clause,
the Purchaser may:

 

		6.2.1	proceed to Completion so far as practicable having regard to the defaults which have occurred without
prejudice to all other rights and remedies available to it, including the right to claim damages; or

 

		6.2.2	terminate this Agreement in which event:

 

		(a)	the Vendors shall indemnify the Purchaser and keep the Purchaser indemnified against all fees and
costs (including, without limitation, professional, accounting and legal costs) incurred by the Purchaser in the negotiation, preparation,
execution or termination of this Agreement; and

 

		(b)	the rights and obligations of the Purchaser and the Vendors shall cease immediately on termination
save for each party's accrued rights and obligations at the date of termination.

 

		7	COMPLETION

 

		7.1	Date and Place

 

Completion of this Agreement shall
take place at the office of the Purchaser (or at such other location as the Parties may agree) on the Completion Date.

 

		7.2	Vendors’ Obligations

 

		7.2.1	At Completion, the Vendors shall deliver or cause to be delivered to the Purchaser the following:

 

		(a)	certified true copy of directors’ and shareholders’ resolutions of the Company appointing
such persons as the Purchaser may nominate as directors; and

 

		(b)	certified true copy of directors’ resolutions of the Company revoking all existing authorities
to bankers of the Company in respect of the operation of its bank accounts and giving authority in favour of such persons as the
Purchaser may nominate to operate such accounts; and

 

		7.2.2	At Completion, the Vendors shall procure the Stakeholder to deliver the Stake Documents to the
Purchaser.

 

    	 	 	 

     

    

 

		7.3	Purchaser’s Obligations

 

		7.3.1	On the Completion Date, against compliance by the Vendors with Clauses 7.2.1 and 7.2.2, the Vitaxel
shall issue the Vitaxel Shares to the Vendors.

 

		7.4	Right to Terminate

 

If the documents required to be
delivered on Completion are not forthcoming for any reason or if in any other respect the provisions of this Clause 7 are not fully
complied with by any Party, the other Party shall be entitled (in addition to and without prejudice to all other rights and remedies
available to it, including the right to claim damages):

 

		7.4.1	to elect to terminate this Agreement without liability on its part in which event:

 

		(a)	the defaulting Party shall indemnify the non-defaulting Party and keep the non-defaulting Party
indemnified against all fees and costs (including, without limitation, professional, accounting and legal costs) incurred by the
non-defaulting Party in the negotiation, preparation, execution or termination of this Agreement or the fulfilment of any of the
Conditions Precedent; and

 

		(b)	the rights and obligations of the Purchaser and the Vendors shall cease immediately on termination
save for each party's accrued rights and obligations at the date of termination.

 

		7.4.2	to effect Completion so far as practicable having regard to the defaults which have occurred without
prejudice to its rights.

 

		8	POST COMPLETION

 

The Vendors undertake to procure
the Company to notify the Company’s financier, on Completion, of any change to the board of directors of the Company and
in accordance with the terms of the financing arrangements or other facilities granted to the Company, if required.

 

		9	REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS

 

		9.1	Vendors’ Warranties

 

Each Vendor represents, warrants
and undertakes to the Purchaser that:

 

		9.1.1	Each of the Vendors jointly and severally represents and
warrants to the Purchaser that each of them has full legal right and power, authority and capacity, and no further action, approval
or consent is required to be taken or obtained for it, to enter into and perform this Agreement which when executed will constitute
valid and binding obligations on the Vendors, in accordance with their respective terms;

 

    	 	 	 

     

    

 

		9.1.2	all the Sale Shares of the Vendors will on Completion represent 100% of the issued and paid up
capital of the Company;

 

		9.1.3	The Company has been duly incorporated and is validly existing under the laws of British Virgin
Islands, and the Company has all power and authority (corporate and otherwise) to own its assets and carry on the Business as conducted
at the date of this Agreement.

 

		9.1.4	No resolution has been passed or order made or petition presented for the winding up or bankruptcy,
as the case may be, of the Company or the Vendors.

 

		9.1.5	The Vendors’ Warranties will survive Completion and continue in full force and effect notwithstanding
Completion.

 

		9.1.6	Each Vendor understands that the Vitaxel Shares are being offered and made in reliance on one or
more exemptions from the registrations requirements of United States federal and state securities laws and that the Purchaser and
Vitaxel are relying upon the truth accuracy of the representations, warranties, agreements, acknowledgments and understandings
of the Vendors set forth herein in order to determine the applicability of such exemptions and the suitability of the Vendors to
acquire the Vitaxel Shares.

 

		9.1.7	Each Vendor is acquiring the Vitaxel Shares for his own account and not with a view to its distribution
within the meaning of Section 2(11) of the Securities Act of 1933, as amended. Each Vendor is not a US person (as that term is
defined in Regulation S Promulgated under the Securities Act). Each Vendor is an “accredited investor” (as that term
is defined in Rule 501 of the General Rules and Regulations under the Securities Act by reason of Rule 501(a)(3)), and each Vendor
is (i) experienced in making investments of the kind represented by the Vitaxel Shares, (ii) able, by reason of his business and
financial experience and professional advisors (who are not affiliated with or compensated in any way by Purchaser or any of its
affiliates), to protect his own interests in connection with the transactions described in this Agreement, and (iii) able to afford
the entire loss of the investment in Vitaxel Shares.

 

    	 	 	 

     

    

 

		9.1.8	Each Vendor was afforded (i) the opportunity to ask such questions as he deemed necessary of, and
to receive answers from, representatives of the Company concerning the merits and risks of acquiring the Vitaxel Shares; (ii) the
right of access to information about Vitaxel and its financial condition, results of operations, business, properties, management
and prospects sufficient to enable such Vendor to evaluate the Vitaxel Shares; and (iii) the opportunity to obtain such additional
information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to acquiring the securities, in addition to having access to the filings made by Vitaxel with
the Securities and Exchange Commission.

 

		9.1.9	Each Vendor understands that the Vitaxel Shares shall be “restricted” (as that term
is defined Rule 144 promulgated under the Securities Act), and each certificate representing the Shares shall be endorsed with
one or more of the following restrictive legends, in addition to any other legend required to be placed thereon by applicable federal
or state securities laws:

 

“The
securities are being offered to investors who are not U.S. persons (as defined in regulation S under the Securities act of 1933,
as amended (“the securities act”)) and without registration with the united states securities and exchange commission
under the securities act in reliance upon regulation s promulgated under the securities act. 

 

Transfer
of these securities is prohibited, except in accordancw with the provisions of regulation s, pursuant to registration under the
securities act, or pursuant to available exemption from registration. Hedging transactions may not be conducted unless in compliance
with the securities act.”

 

		9.1.10	None of the Vendors nor the Company has knowledge of any fact that has specific application to
the Company or the Sale Shares and that may materially adversely affect the Shares or the assets, business, prospects, financial
condition or results of operations of Company that has not been set forth in the Agreement. There does not now exist any event,
condition, or other matter, or any series of events, conditions or other matters, individually or in the aggregate, adversely affecting
the Sale Shares or the Company’s assets, business prospects, financial conditions or results of its operations that has not
been specifically disclosed to Purchaser in this Agreement.

 

		9.2	Purchaser’s Warranties

 

The Purchaser represents,
warrants and undertakes to each of the Vendors that:

 

		9.2.1	it is a company duly incorporated and validly existing under the laws of Malaysia;

 

		9.2.2	it has the legal right and full power and authority, and no further action, approval or consent
is required to be taken or obtained for it, to enter into and perform this Agreement which when executed will constitute valid
and binding obligations on the Purchaser, in accordance with their respective terms; and

 

    	 	 	 

     

    

 

		9.2.3	the execution and delivery of, and the performance by the Purchaser of its obligations under this
Agreement will not and are not likely to:

 

		(a)	result in a breach of any provision of the memorandum or articles of association or constitutional
documents of the Purchaser; or

 

		(a)	result in a breach of, or give any third party a right
to terminate or modify, or result in the creation of any Security Interest under, any agreement, licence or other instrument or
result in a breach of any order, judgment or decree of any Court, governmental agency or regulatory body to which the Purchaser
is a party or by which the Purchaser or any of its assets is bound.

 

9.2.4       The
Purchaser shall procure and ensure the passing of board of directors’ resolution and shareholders’ resolution (if required)
of the Purchaser approving:

 

		(a)	the purchase of the Sale Shares from the Vendors; and

 

		(b)	the execution of this Agreement by the Purchaser,

 

in accordance with the terms and
subject to the conditions of this Agreement.

 

		9.3	Vitaxel’s Warranties

 

Vitaxel represents, warrants
and undertakes to each of the Vendors that:

 

		9.3.1	Vitaxel has been duly incorporated and is validly existing under the laws of the State of Nevada,
USA, and the Company has all power and authority (corporate and otherwise) to own its assets and carry on the Business as conducted
at the date of this Agreement.

 

		9.3.2	Vitaxel shall procure and ensure the passing of board of directors’ resolution and shareholders’
resolution (if required) of the Company approving:

 

		(a)	the purchase by the Purchaser of the Sale Shares;

 

		(b)	the issue of the new share certificates in respect of the
Sale Shares in favour of the Vendors; and

 

		(c)	the entering into the Register of Members of Vitaxel, the
name of the Vendors, as the holders of the Vitaxel Share;

 

in accordance
with the terms and subject to the conditions of this Agreement.

 

		9.3.3	The Vitaxel Shares to be issued to the Vendors shall be
properly and validly authorised, allotted and/or issued as fully paid up and rank pari passu in respects with each other and all
existing shares of Vitaxel. They will not be entitled to any dividends declared before the Completion date but will be entitled
to all dividends declared and paid after the Completion date.

 

    	 	 	 

     

    

 

		10	USE OF INTELLECTUAL PROPERTY RIGHTS

 

Each
of the Vendors confirms and undertakes that he shall not, following Completion, either alone or jointly with, through or as manager,
adviser, consultant or agent for any person, directly or indirectly, use any of the Intellectual Property Rights, and in particular
shall not use any name, mark or get-up in any manner which may result or is likely to result in confusion between or other association
with the business, goods, services or other activities of the Company.

 

		11	TERMINATION OF AGREEMENT

 

		11.1	Termination by the Vendors

 

If before
or on the Completion Date:

 

		11.1.1	there is a breach of any representation or warranty which
is made by the Purchaser in or pursuant to the terms of this Agreement; or

 

		11.1.2	there is a breach of any material terms or conditions of this Agreement or a failure to perform
or observe any material undertaking, obligation or agreement in this Agreement by the Purchaser; or

 

		11.1.3	a petition for winding up is presented against the Purchaser; or

 

		11.1.4	an order is made or a member’s resolution is passed for the winding up of the Purchaser;
or

 

		11.1.5	an administrator, a receiver and/or manager is appointed by the court or pursuant to any statute
or regulation or by any creditor pursuant to a debenture or any other security document in favour of such creditor over the undertaking,
assets and properties of the Purchaser or any part of its assets and properties; or

 

		11.1.6	an event analogous to any of the Clauses 11.1.3, 11.1.4, 11.1.5 above has occurred in any jurisdiction;

 

then provided where the default is,
in the opinion of the Vendors, capable of being remedied, is not remedied within [fourteen (14)] days commencing
on the day immediately after the date the Vendors give written notice to the Purchaser and to the satisfaction of the Vendors,
the Vendors may terminate this Agreement with immediate effect by giving written notice to the Purchaser before or on the Completion
Date in which event Clause 3.4 shall apply. None of the Parties shall have any claim against the others for costs, damages, compensation
or otherwise save for any claim by the Vendors against the Purchaser for costs and expenses incurred by the Vendors up to the termination
of this Agreement

 

    	 	 	 

     

    

 

		11.2	Termination by the Purchaser

 

If, before or on the Completion
Date:

 

		11.2.1	it shall be found that any of the Vendors’ Warranties was, when given, or will be or would
be, at Completion (as if they had been given again at Completion) not complied with or otherwise untrue or misleading in any material
respect; or

 

		11.2.2	there is a breach of any material terms or conditions of this Agreement or a failure to perform
or observe any material undertaking, obligation or agreement in this Agreement by any Vendor; or

 

		11.2.3	a petition for bankruptcy is presented against the individual Vendor; or

 

		11.2.4	an administrator, a receiver and/or manager is appointed by the court or pursuant to any statute
or regulation or by any creditor pursuant to a debenture or any other security document in favour of such creditor over the undertaking,
assets and properties of the Vendors or any part of its/their assets and properties; or

 

		11.2.6	an event analogous to any of the Clauses 0(c), (d) or (e) above has occurred in any jurisdiction;
or

 

		11.1.7	any Licence required for the operation of the Business of the Company will have been suspended
or revoked; or

 

		11.1.8	any event occurs which affects or is likely to affect materially and adversely the financial position
or business prospects of the Company;

 

then provided where the default
is, in the opinion of the Purchaser capable of being remedied, is not remedied within fourteen (14) days commencing on the day
immediately after the date the Purchaser gives written notice to the Vendors and to the satisfaction of the Purchaser, the Purchaser
may terminate this Agreement with immediate effect by giving written notice to the Vendors before or on the Completion Date in
which event Clause 4.4 shall apply. None of the Parties shall have any claim against the others for costs, damages, compensation
or otherwise, save for any claim by the Purchaser against the Vendors for costs and expenses incurred by the Purchaser up to the
termination of this Agreement.

 

		12	ANNOUNCEMENT

 

		12.1	Subject to Clause 12.2, the Purchaser, Vendors or
Vitaxel shall not make or send before or after Completion, any announcement, communication or circular relating to the Transaction
unless such Party has first obtained the other Party's written consent to the form and text of such announcement, such consent
not to be unreasonably withheld.

 

    	 	 	 

     

    

 

		12.2	Clause 12.1 does not apply to an announcement, communication
or circular:

 

		12.2.1	required by law or by the rules of any stock exchange or
by court or by any regulatory or governmental authority, body or agency, in which event the Party required to make or send such
announcement, communication or circular shall, where practicable, first consult with the other Party as to the content of such
announcement; or

 

		12.2.2	made or sent by the Purchaser after Completion to the Company's
customers, clients or suppliers advising them of the change of control of the Company.

 

		13	CONFIDENTIALITY

 

		13.1	Subject to Clauses 12, 13.2 and 13.3, the Parties will:

 

		13.1.1.	treat as strictly confidential and not disclose or use any information received or obtained as
a result of entering into this Agreement (or any agreements entered into pursuant to this Agreement) which relates to:

 

		(a)	the existence, the provisions or the subject matter
of this Agreement or any agreements entered into pursuant to this Agreement or any document referred to in such agreements; or

 

		(b)	the negotiations relating to this Agreement or any
agreements entered into pursuant to this Agreement;

 

		13.1.2	not copy, make use of or disclose to any person Confidential
Information; and

 

		13.1.3.	take all reasonable steps to prevent the copy, use or disclosure
of any such Confidential Information.

 

		13.2	Any Party may disclose information which would otherwise
be confidential if and to the extent:

 

		13.2.1	reasonably required to give effect to the terms of this
Agreement;

 

		13.2.2.	required by law of any relevant jurisdiction;

 

		13.2.3.	required by any securities exchange or regulatory or governmental
body to which that Party is subject or submits wherever situated whether or not the requirement for information has the force
of law;

 

		13.2.4.	disclosed on a confidential basis to the directors, officers,
employees, professional advisers or other representatives of that Party (collectively, “Authorised Persons”)
provided that such Authorised Person have agreed to be similarly bound by the confidentiality provisions contained in this Agreement;

 

    	 	 	 

     

    

 

		13.2.5	the information has come into the public domain through no fault of that Party;

 

		13.2.6.	required to enable that Party to enforce its rights under this Agreement;

 

		13.2.7.	prior written approval has been given by the other Party;

 

provided that any such information
disclosed pursuant to Clause 13.2.1 or 13.2.2 or 13.2.3 will (unless otherwise required by law) be disclosed only after notice
to the Vendors in the case of the Purchaser, or the Purchaser in the case of the Vendors.

 

		13.3	The restrictions contained in this Clause will continue to apply after the termination of this
Agreement.

 

		14	NOTICE

 

		14.1	Service of Notice

 

Any notices, demands or other communications
required or permitted, under this Agreement shall be in writing and delivered personally or sent by prepaid registered post to
the address of the relevant Party set out in Clause 0, or by sending it by facsimile to the facsimile number of the relevant Party
set out in Clause 0 or to such other address or facsimile number as a Party may from time to time duly notify the other in writing.

 

The addresses and facsimile numbers
of the Parties for the purpose of this Agreement are specified below:

 

		14.1.1	The Vendors

 

	Lim Hui Sing:	 
	Address:	No 27, Jln Du 4/7, Taman Damai Utama, 47180
	 	Puchong, Selangor
	 	 
	Leong Yee Ming:	 
	 Address:	11-2-3, Menara Antara, Jln Bkt Ceylon Menara
	 	Antara, 50200 Kuala Lumpur, WP Kuala Lumpur

 

		14.1.2	The Purchaser

 

	Authorised representative:	Lim Wee Kiat
	Address of Purchaser:	Wisma Ho Wah Genting, No 35, Jalan 
	 	Maharajalela, 50150 Kuala Lumpur 

 

		14.1.3	Vitaxel Group Limited

 

	Authorised representative:	Lim Wee Kiat
	Address of Vitaxel	Wisma Ho Wah Genting, No 35, Jalan 
	 	Maharajalela, 50150 Kuala Lumpur 

 

    	 	 	 

     

    

 

		14.2	Time of Service

 

Any notices, demands or other communications
shall be deemed to have been served:

 

		14.2.1	if delivered personally, when left at the addressed referred
to in Clause 0;

 

		14.2.2	if posted within Malaysia to a Malaysian address, three (3) Business Days after posting and in
any other case, seven (7) Business Days after posting;

 

		14.2.3	if served by facsimile, subject to Clause 0(d) below, at the time indicated on the transmission
report produced by the sender’s facsimile machine indicating that the facsimile was sent in its entirety to the addressee’s
facsimile; and

 

		14.2.4	if received after 6.00 p.m. on a Business Day or at any time on a day which is not a Business Day
in the place of receipt, at 9.00 a.m. on the next Business Day.

 

		14.3	In proving service of notices, demands or other communications, it shall be sufficient to show
that personal delivery was made or that the envelope containing such notice was properly addressed, and duly stamped and posted
or that the facsimile transmission was properly addressed and despatched.

 

		15	TIME

 

Time is of the
essence as regards to all dates, periods of time and times specified in this Agreement.

 

		16	WAIVER AND EXERCISE OF RIGHTS

 

		16.1	A single or partial exercise or waiver of a right relating to this Agreement does not prevent any
other exercise of that right or the exercise of any other rights.

 

		16.2	No Party will be liable for any loss or expenses incurred by another Party caused or contributed
to by the waiver, exercise, attempted exercise, failure to exercise or delay in the exercise of a right.

 

		17	SEVERABILITY

 

		17.1	If a provision in this Agreement is held to be illegal, invalid, void, voidable or unenforceable,
that provision must be read down to the extent necessary to ensure that it is not illegal, invalid, void, voidable or unenforceable.

 

		17.2	If it is not possible to read down a provision as required in Clause 17.1, that provision is severable
without affecting the validity or enforceability of the remaining part of that provision or the other provisions in this Agreement.

 

    	 	 	 

     

    

 

		18	COSTS

 

Each Party shall bear its own legal,
professional and other costs and expenses incurred by it in connection with the negotiation, preparation or completion of this
Agreement, and the sale and purchase of the Sale Shares. The Purchaser shall bear all stamp duties, if any, payable in connection
with the transfer of the Sale Shares.

 

		19	SET OFF

 

All sums payable by or on behalf
of any Party shall be paid free and clear of all deductions or withholdings whatsoever, save only as may be required to be made
by the paying party by law.

 

		20	SUCCESSORS-IN-TITLE AND ASSIGNEES

 

		20.1	This Agreement is binding on the Parties and their respective
successors-in-title and permitted assigns, as the case may be. Any reference in this Agreement to any of the Parties shall be
construed accordingly.

 

		20.2	The Vendors shall not assign or transfer any of their rights, privileges, liabilities or obligations
under this Agreement in whole or in part to any other party or parties without the prior written consent of the Purchaser.

 

		20.3	The Purchaser shall be entitled to assign or transfer in any manner, its rights, privileges,
liabilities or obligations under this Agreement in whole or in part to any other party or parties without the prior written consent
of any of the Vendors.

 

		20.4	This Agreement will continue to be valid and binding notwithstanding any change, by amalgamation,
liquidation, reconstruction or otherwise, in the constitution of any of the Parties and it is expressly declared that no change
of any sort in relation to or affecting any of the Parties will in any way affect the liabilities and/or obligations created under
this Agreement in relation to any transaction whether past, present or future.

 

		21	COUNTERPARTS

 

This Agreement may be executed
in any number of counterparts, all of which taken together constitute one instrument.

 

		22	WHOLE AGREEMENT

 

		22.1	This Agreement constitutes the whole agreement between
the Parties. This Agreement supersedes and extinguishes any previous agreements between the Parties, whether orally or in writing,
in respect of the Transaction which shall cease to have any further force or effect.

 

		22.2	No variation of this Agreement shall be effective unless made in writing and signed by or on behalf
of the Purchaser and each of the Vendors.

 

    	 	 	 

     

    

 

		23	SPECIFIC PERFORMANCE

 

Any Party will
be entitled to the rights of specific performance against the others under the provisions of this Agreement and it is mutually
agreed that in the event of any Party exercising its right to specific performance of this Agreement, an alternative remedy of
monetary compensation will not be regarded as compensation or sufficient compensation for the other Party's default in the performance
of the terms and conditions of this Agreement.

 

		24	GOVERNING LAW

 

This Agreement is governed by and
is to be construed in accordance with the laws of Malaysia. Each Party irrevocably and unconditionally submits to the exclusive
jurisdiction of the courts of Malaysia and waives any right to object to proceedings being brought in those courts.

 

The
rest of this page is intentionally left blank.

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the Parties hereto
have set their hands on the date hereinabove written

 

	VENDORS	 	 
	 	 	 
	SIGNED by LIM HUI SING	 	)
	(NRIC No.: A31045777)	 	)
	in the presence of:	 	)
	 	 	 
	/s/ LIM HUI SING	 	 
	Witness’s signature	 	 
	Name:	 	 
	NRIC No.:	 	 
	 	 	 
	SIGNED by	 	)
	LEONG YEE MING	 	)
	(NRIC No.: A41282606)	 	)
	in the presence of:	 	)
	 	 	 
	/s/ LEONG YEE MING	 	 
	Witness’s signature	 	 
	Name:	 	 
	NRIC No.:	 	 
	 	 	 
	PURCHASER	 	 
	 	 	 
	SIGNED by Lim Wee Kiat	 	)
	(NRIC No.: A41143472)	 	)
	for and on behalf of VITAXEL SDN BHD	 	)
	(Company No: 1013530U)	 	)
	in the presence of:	 	)
	 	 	 
	/s/ Lim Wee Kiat	 	 
	Witness’s signature	 	 
	Name:	 	 
	NRIC No.:	 	 
	 	 	 
	VITAXEL GROUP LIMITED	 	 
	 	 	 
	SIGNED by Lim Wee Kiat	 	)
	(NRIC No.: A41143472)	 	)
	for and on behalf of VITAXEL GROUP LIMITED	 	)
	(Registration No: E0556682013-0)	 	)
	in the presence of:	 	)
	 	 	 
	/s/ Lim Wee Kiat	 	 
	Witness’s signature	 	 
	Name:	 	 
	NRIC No	 	 

 

    	 	 	 

     

    

 

SCHEDULE 1

 

VENDORS, SALE SHARES AND CONSIDERATION

 

	Name	 	Number of
 Sale Shares
	 	Percentage
 of
 Shareholding
	 	 	Number of
 Vitaxel Shares
	 
	LIM HUI SING	 	2	 	 	50	%	 	 	37,500,000	 
	LEONG YEE MING	 	2	 	 	50	%	 	 	37,500,000	 
	TOTAL	 	4	 	 	100	%	 	 	75,000,000	 

 

    	 	 	 

     

    

 

Appendix
I

 

Conditions Precedent

 

		1.	Upon successful increase of Vitaxel Group Limited’s authorized share of capital stock.

 

		2.	Upon the approval of necessary authority (if any).

 

		3.	Receipt by Vitaxel of the financial statements as required to be filed under a Current Report on Form 8-K.EX-4.1

 Exhibit 4.1 

NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY
INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF
SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, MAY BE SOLD OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. 

Warrant No. 2017-C-1 

GALECTIN THERAPEUTICS, INC. 

COMMON STOCK PURCHASE WARRANT 

Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), for value received and subject to the terms set forth below
hereby grants to Richard E. Uihlein, or its registered successors and assigns (the “Holder”), the right to purchase from the Company at any time or from time to time until the date and time permitted under Section 2.2 below and
subject to the vesting provisions pursuant to Section 2.1 below, one million (1,000,000) fully paid and non-assessable shares of the Common Stock, at the purchase price of Five Dollars ($5.00) per share
(the “Exercise Price”). This Warrant is issued pursuant to that certain Line of Credit Letter Agreement, dated as of December 19, 2017, by and between the Company and the Holder (the “Line of Credit Letter Agreement”). The
Exercise Price and the number and character of such shares of Common Stock purchasable pursuant to the rights granted under this Warrant are subject to adjustment as provided herein. 

1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Line of Credit Letter Agreement. As used
herein the following terms, unless the context otherwise requires, have the following respective meanings: 
 “Common
Stock” means the Company’s common stock and stock of any other class of securities into which such securities may hereafter have been reclassified or changed into, including any stock (other than Common Stock) and other securities of
the Company or any other Person (corporate or other) which the Holder of this Warrant at any time shall be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to Common Stock, or which at any
time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock pursuant to Section 3.2 hereof or otherwise. 

“Common Stock Equivalents” means any securities of the Company or its subsidiaries which would entitle the
holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles
the holder thereof to receive, Common Stock. 
 “Issue Date” means December 19, 2017. 

“Market Value” means, for any date, the price determined by the first of the following clauses that applies:
(a) if the Common Stock is then listed or quoted on a Trading Market (other than the OTC Bulletin Board), the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which
the Common Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based on a Trading Day from 9:30 a.m. Eastern Time to 4:00 p.m. Eastern Time); (b) if the Common Stock is then listed or quoted on the OTC Bulletin Board, the average
of the high and low price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; or (c) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then
reported in the “Pink Sheets” published by the Pink Sheets, LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported. 

 “This Warrant” means, collectively, this Warrant and all other
stock purchase warrants issued in exchange therefor or replacement thereof. 
 “Trading Day” means a day on
which the common Stock is traded on a Trading Market. 
 “Trading Market” means any of the following markets
or exchanges on which the common Stock is listed or quoted for trading on the date in question: the Nasdaq SmallCap Market, the NYSE Alternext US, the New York Stock Exchange, the Nasdaq National Market, the OTC Bulletin Board or the “Pink
Sheets”. 
 2. Exercise. 
 2.1 Vesting.
This Warrant shall vest (a) with respect to 500,000 shares of Common Stock immediately upon issuance (“Initially Vested Warrants”) and (b) with respect to the remaining 500,000 shares of Common Stock (“Remaining
Warrants”) ratably if and as loan proceeds are advanced to the Company pursuant to the Line of Credit Letter Agreement on or before December 31, 2018, such that this Warrant shall vest with respect to 0.05 shares of Common Stock for each
dollar advanced to the Company pursuant to the Line of Credit Letter Agreement. The Remaining Warrants that are vested are the “Vested Remaining Warrants” and the Remaining Warrants that are not vested ae the “Unvested Remaining
Warrants”). This Warrant may only be exercised with respect to the then-vested portion hereof. Any portion of this Warrant that has not vested by December 31, 2018, shall no longer be able to be vested. At any time on or after
December 31, 2018, the Company may require that this Warrant be exchanged for a new Warrant representing only the vested portion hereof. Any attempted exercise of this Warrant for any unvested portion hereof shall be null and void. 

2.2 Exercise Period. The Holder may exercise this Warrant, to the extent vested pursuant to Section 2.1 above, at any time six months
after the Issue Date and before the close of business in Norcross, Georgia on the seventh (7th) anniversary of the Issue Date (the “Exercise Period”), unless earlier terminated pursuant
to Section 2.7 herein. 
 2.3 Exercise Procedure. 

(a) This Warrant will be deemed to have been exercised with respect to the applicable vested portion hereof at such time as the Company has
received all of the following items (the “Exercise Date”): 
 (i) a completed Exercise Notice as described in
Section 2.5 hereof, executed by the Person exercising all or part of the vested purchase rights represented by this Warrant (the “Purchaser”); 

(ii) this Warrant; 

(iii) if this Warrant is not registered in the name of the Purchaser, an Assignment or Assignments in the form set forth in
Exhibit B hereto, evidencing the assignment of this Warrant to the Purchaser together with any documentation required pursuant to Section 8(a) hereof; and 

(iv) a check payable to the order of the Company in an amount equal to the product of the Exercise Price multiplied by the
number of shares of Common Stock being purchased upon such exercise. 
 (b) As soon as practicable after the exercise of this Warrant in
full or in part, and in any event within ten (10) days after the Exercise Date, the Company at its expense will cause to be issued in the name of and delivered to the Purchaser, or as the Purchaser (upon payment by the Purchaser of any
applicable transfer taxes) may direct, a certificate or certificates for the number of fully paid and non-assessable shares of Common Stock to which the Purchaser shall be entitled upon such exercise, together
with any other stock or other securities and property (including cash, where applicable) to which the Purchaser is entitled upon exercise. 

 (c) Unless this Warrant has expired or all of the purchase rights represented hereby have been
exercised, the Company at its expense will, within ten (10) days after the Exercise Date, issue and deliver to or upon the order of the Purchaser a new Warrant or Warrants of like tenor, in the name of the Purchaser or as the Purchaser (upon
payment by the Purchaser of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock remaining issuable under this Warrant. 

(d) The Common Stock issuable upon the exercise of this Warrant will be deemed to have been issued to the Purchaser on the Exercise Date, and
the Purchaser will be deemed for all purposes to have become the record holder of such Common Stock on the Exercise Date. 
 (e) The
issuance of certificates for shares of Common Stock upon exercise of this Warrant will be made without charge to the Holder or the Purchaser for any issuance tax in respect thereof or any other cost incurred by the Company in connection with such
exercise and the related issuance of shares of Common Stock. 
 (f) The holder represents and warrants that at the time of any exercise of
this warrant the holder is an “accredited investor,” as such term is defined in Rule 501 promulgated under the Securities Act and acknowledges and agrees that the Company may, in its sole discretion, (i) require, as a condition to the
exercise of this Warrant, that the holder provide such written evidence that such holder is an accredited investor as the time of exercise, and (ii) decline to issue the shares of Common Stock issuable upon such exercise if the Company is not
satisfied that this warrant may be exercised by the holder pursuant to a valid registration exemption from the Securities Act and any applicable state securities law. 

2.4 Acknowledgement of Continuing Obligations. The Company will, at the time of the exercise of this Warrant, upon the request of the
Purchaser, acknowledge in writing its continuing obligation to afford to the Purchaser any rights to which the Purchaser shall continue to be entitled after such exercise in accordance with the provisions of this Warrant, provided that if the
Purchaser shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to the Purchaser any such rights. 

2.5 Exercise Notice. The Exercise Notice will be substantially in the form set forth in Exhibit A hereto, except that if the shares of Common
Stock issuable upon exercise of this Warrant are not to be issued in the name of the Purchaser, the Exercise Notice will also state the name of the Person to whom the certificates for the shares of Common Stock are to be issued, and if the number of
shares of Common Stock to be issued does not include all the shares of Common Stock issuable hereunder, it will also state the name of the Person to whom a new Warrant for the unexercised portion of the rights hereunder is to be delivered. 

2.6 Fractional Shares. If a fractional share of Common Stock would, but for the provisions of Section 2.2 hereof, be issuable upon
exercise of the rights represented by this Warrant, the Company will, within ten (10) days after the Exercise Date, deliver to the Purchaser a check payable to the Purchaser in lieu of such fractional share, in an amount equal to the Market
Value of such fractional share as of the close of business on the Exercise Date. 
 3. Adjustments. 

3.1 Adjustments for Stock Splits, Etc. If the Company shall at any time after the Issue Date subdivide its outstanding Common Stock, by split-up or otherwise, or combine its outstanding Common Stock, or issue additional shares of its capital stock in payment of a stock dividend in respect of its Common Stock, the number of shares issuable on the
exercise of the unexercised portion of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Exercise Price then applicable to
shares covered by the unexercised portion of this Warrant shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or proportionately increased in the case of combination. 

3.2 Adjustment for Reclassification, Reorganization, Etc. In case of any reclassification, capital reorganization, or change of the
outstanding Common Stock (other than as a result of a subdivision, combination or stock dividend), or in the case of any consolidation of the Company with, or merger of the Company into, another Person (other than a

 
consolidation or merger in which the Company is the continuing corporation and which does not result in any reclassification or change of the outstanding Common Stock of the Company), or in case
of any sale or conveyance to one or more Persons of the property of the Company as an entirety or substantially as an entirety at any time prior to the expiration of this Warrant, then, as a condition of such reclassification, reorganization,
change, consolidation, merger, sale or conveyance, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder of this Warrant, so that the Holder of this Warrant
shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, the kind and amount of shares of stock and other
securities and property receivable upon such reclassification, reorganization, change, consolidation, merger, sale or conveyance by a holder of the number of shares of Common Stock of the Company as to which this Warrant was exercisable immediately
prior to such reclassification, reorganization, change, consolidation, merger, sale or conveyance, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder of this Warrant to the end that the
provisions hereof (including, without limitation, provisions for the adjustment of the Exercise Price and of the number of shares purchasable upon exercise of this Warrant) shall thereafter be applicable in relation to any shares of stock, and other
securities and property, thereafter deliverable upon exercise hereof. If, as a consequence of any such transaction, solely cash, and no securities or other property of any kind, is deliverable upon exercise of this Warrant, then, in such event, the
Company may terminate this Warrant by giving the Holder hereof written notice thereof. Such notice shall specify the date (at least thirty (30) days subsequent to the date on which notice is given) on which, at 3:00 P.M., Norcross, Georgia
time, this Warrant shall terminate. Notwithstanding any such notice, this Warrant shall remain exercisable, and otherwise in full force and effect, until such time of termination. 

3.3 Certificate of Adjustment. Whenever the Exercise Price or the number of shares issuable hereunder is adjusted, as herein provided, the
Company shall promptly deliver to the registered Holder of this Warrant a certificate of the Treasurer of the Company, which certificate shall state (i) the Exercise Price and the number of shares of Common Stock issuable hereunder after such
adjustment, (ii) the facts requiring such adjustment, and (iii) the method of calculation for such adjustment and increase or decrease. 

3.4 Small Adjustments. No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or
decrease in the Exercise Price of at least one percent; provided, however, that any adjustments which by reason of this Section 3.5 are not required to be made immediately shall be carried forward and taken into account at the time of exercise
of this Warrant or any subsequent adjustment in the Exercise Price which, singly or in combination with any adjustment carried forward, is required to be made under Sections 3.1 or 3.2.  

4. Reservation of Stock, etc., Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely for issuance and
delivery upon the exercise of this Warrant, all shares of Common Stock from time to time issuable upon the exercise of this Warrant. 
 5. Disposition of
This Warrant, Common Stock, Etc. 
 (a) The Holder of this Warrant and any transferee hereof or of the Common Stock with respect to which
this Warrant may be exercisable, by their acceptance hereof, hereby understand and agree that this Warrant and the Common Stock with respect to which this Warrant may be exercisable have not been registered under the Securities Act, and may not be
sold, pledged, hypothecated, donated, or otherwise transferred (whether or not for consideration) without an effective registration statement under the Act or an opinion of counsel satisfactory to the Company and/or submission to the Company of such
other evidence as may be satisfactory to counsel to the Company, in each such case, to the effect that any such transfer shall not be in violation of the Act. It shall be a condition to the transfer of this Warrant that any transferee thereof
deliver to the Company its written agreement to accept and be bound by all of the terms and conditions of this Warrant. 

 (b) Except to the extent the resale of the shares of Common Stock issuable upon exercise hereof
are registered for resale, or may be sold to the public pursuant to Rule 144(b)(1) under the Securities Act, the certificates of the Company that will evidence the shares of Common Stock with respect to which this Warrant may be exercisable will be
imprinted with a conspicuous legend in substantially the following form: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, PLEDGED, HYPOTHECATED, DONATED OR OTHERWISE TRANSFERRED (WHETHER OR NOT FOR CONSIDERATION) BY THE HOLDER WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND/OR SUBMISSION TO THE COMPANY OF SUCH OTHER EVIDENCE AS MAY BE SATISFACTORY TO COUNSEL TO THE COMPANY, IN EACH SUCH CASE, TO THE EFFECT THAT ANY SUCH TRANSFER SHALL NOT
BE IN VIOLATION OF THE ACT.” 
 The Company agrees to prepare and file with the Securities Exchange Commission within 180 days from the
date hereof a registration statement covering the resale of the shares of Common Stock that are issuable with respect to this Warrant. Except as provided in the foregoing sentence, the Company has not agreed to register any of the Holder’s
shares of Common Stock of the Company with respect to which this Warrant may be exercisable for distribution in accordance with the provisions of the Securities Act, and the Company has not agreed to comply with any exemption from registration under
the Act for the resale of the Holder’s shares of Common Stock with respect to which this Warrant may be exercised. Hence, it is the understanding of the Holder of this Warrant that by virtue of the provisions of certain rules respecting
“restricted securities” promulgated by the SEC, the shares of Common Stock of the Company with respect to which this Warrant may be exercisable may be required to be held indefinitely, unless and until registered under the Securities Act,
unless an exemption from such registration is available, in which case the Holder may still be limited as to the number of shares of Common Stock of the Company with respect to which this Warrant may be exercised that may be sold from time to time.

 6. Rights and Obligations of Warrant Holder. The Holder of this Warrant shall not, by virtue hereof, be entitled to any voting rights or other
rights as a stockholder of the Company. No provision of this Warrant, in the absence of affirmative actions by the Holder to purchase Common Stock of the Company by exercising this Warrant, and no enumeration in this Warrant of the rights or
privileges of the Holder, will give rise to any liability of such Holder for the Exercise Price of Common Stock acquirable by exercise hereof or as a stockholder of the Company. 

7. Transfer of Warrants. Subject to compliance with the restrictions on transfer applicable to this Warrant referred to in Section 5 hereof, this
Warrant and all rights hereunder are transferable, in whole or in part to other Lenders pursuant to the Line of Credit Letter Agreement, without charge to the registered Holder, upon surrender of this Warrant with a properly executed Assignment (in
substantially the form attached hereto as Exhibit B), to the Company, and the Company at its expense will issue and deliver to or upon the order of the Holder hereof a new Warrant or Warrants in such denomination or denominations as may be
requested, but otherwise of like tenor, in the name of the Holder or as the Holder (upon payment of any applicable transfer taxes) may direct. 
 8.
Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity
agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like
tenor. 
 9. Company Records. Until this Warrant is transferred on the books of the Company, the Company may treat the registered Holder hereof as
the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
 10. Miscellaneous. 

10.1 Notices. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class mail, postage prepaid, to such
address as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and at the address of the last Holder of this Warrant who has so 

 
furnished an address to the Company. All communications from the Holder of this Warrant to the Company shall be mailed by first class mail, postage prepaid, to Galectin Therapeutics, Inc., 4960
Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, Attn: Chief Financial Officer, or such other address as may have been furnished to the Holder in writing by the Company. 

10.2 Amendment and Waiver. Except as otherwise provided herein, this Warrant and any term hereof may be amended, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement of such amendment, waiver, discharge or termination is sought. 
 10.3 Governing Law;
Descriptive Headings. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Nevada. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of
the terms hereof. 
 [SIGNATURE ON FOLLOWING PAGE] 

 Dated:    December 19, 2017. 

 

			
	GALECTIN THERAPEUTICS, INC.
		
	By:	 	 /s/ Peter G. Traber

	Name:	 	Peter G. Traber
	Title:	 	CEO

 EXHIBIT A 

EXERCISE NOTICE 
 [To be signed
only upon exercise of Warrant] 
  

			
	 To:
	  	Date:

 The undersigned, the Holder of the within Warrant, pursuant to the provisions set forth in the within Warrant,
hereby irrevocably elects to exercise the vested purchase rights represented by such Warrant for, and agrees to subscribe for and purchase thereunder,
                 shares of the Common Stock covered by such Warrant and herewith makes payment of
$             therefor, and requests that the certificates for such shares be issued in the name of, and delivered to,
                    , whose address is:
                                        .
If said number of shares is less than all the shares covered by such Warrant, a new Warrant shall be registered in the name of the undersigned and delivered to the address stated below. 

 

			
	Signature	 	  

		
		 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant or on the form of Assignment attached as Exhibit B thereto.)
		
	Address	 	  

		
		 	  

		
	[Signature Guarantee]	 	

 EXHIBIT B 

ASSIGNMENT 
 [To be signed only
upon transfer of Warrant] 
 For value received, the undersigned hereby sells, assigns and transfers all of the rights of the undersigned
under the within Warrant with respect to the number of shares of the Common Stock covered thereby set forth below, unto: 
  

			
	 Name of Assignee
	  	Address
		
	 No of Shares: Initially Vested Warrants
                    

No of Shares: Vested Remaining Warrants
                    

No of Shares: Unvested Remaining Warrants
                    
	  	

  

							
	
Dated:                     
       
	 		 	Signature	 	  

				
		 		 		 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant.)
				
		 		 	Address

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]